Wits RHI PEPFAR COVID-19 Response
Wits RHI PEPFAR funded programmes (Tshwane CDC, Lejweleputswa APACE and Key Populations - USAID) in collaboration with PASP – ELMA, Project PrEP – UNITAID, and School-Based Programme - USAID) have established a PEPFAR RHI COVID-19 Response Committee which serves as a nerve centre to coordinate an internal Wits RHI COVID-19 response and to leverage resources and best practices between the programmes.
Download full COVID-19 project listing
COVID-19 Surveillance in Pregnant Women and Household Contacts
The Pregnancy Surveillance Study aims to evaluate the impact of SARS-CoV-2 in pregnancy and household contacts of pregnant women since there is insufficient research on this population. This study will determine the natural history of symptomatic SARS-CoV-2 infection in pregnancy, including the potential for vertical transmission, among HIV-uninfected pregnant individuals and those living with HIV.
Download full COVID-19 project listing
The South African Ox1Cov-19 Vaccine VIDA-Trial
The COVID-19 Digital Risk Assessment and Mapping known as HealthCheck
In a collaborative effort, Wits RHI’s is collaborating with Praekelt and the NDOH to build a USSD and WhatsApp Digital Risk Assessment and Mapping Tool called “COVID-19 HealthCheck”. The NDOH WhatsApp platform that houses the HealthCheck tool, has become the most highly utilized platform for users in South Africa currently serving millions of South Africans.
Download full COVID-19 project listing
Novavax 2019nCOV501
This project aims to assess a Phase 2A/B, randomized, observer-blinded, placebo controlled study to evaluate the efficacy, immunogenicity, and safety of a SARS-cov-2 recombinant spike protein nanoparticle vaccine (SARS-cov-2 RS) with matrix-adjuvant in South African adult subjects living without HIV; and safety and immunogenicity in adults living with HIV
Download this single project brief
Download full project listing
COVID Vaccine Implementation Science
DAISY - Specific Aim 3
This project aims to measure acceptability of, and preferences for the DAISY drug delivery platform among two key end-user groups in South Africa (SA): caregivers of HIV-positive children receiving antiretroviral therapy (ART) and health care providers.
These end-user perspectives are linked to the Target Product Profile (TPP) and will inform design of the DAISY, including device and applicator characteristics.
Download this single project brief
Download full project listing